Project Grant R01AI182217
Award Date
9/5/24
Completion Date
8/31/29
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
North Chicago, IL 60064, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $650,020.00 in funding to the University of Georgia Research Foundation, Inc. to conduct research on the role of regulatory T cells (Tregs) in recurring malaria infections. The primary objective of this 5-year research project is to determine the mechanisms by which memory Tregs (mTregs) generated during initial...
This Project Grant award of $184,109, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research on modulating monocyte and T cell functions during subclinical malaria. The grantee, the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, will investigate the role of immune inhibitory receptors LILRB1 and LILRB2 in regulating innate and adaptive immune...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $832,071 to Seattle Children's Hospital to develop a universal transmission-blocking vaccine against malaria. The key products and services to be delivered include: Developing potent transmission-reducing monoclonal antibodies that can block vector infection across Plasmodium falciparum and Plasmodium vivax species. This...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $310,492 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the University of Washington. The grant, titled "Understanding and Overcoming Plasmodium-Specific Immune Evasion Mechanisms," aims to investigate how Plasmodium infection influences the pre-vaccine memory B cell pool to understand why current malaria vaccines have limited efficacy in endemic areas. The research...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $690,500 to Boston University Medical Campus to investigate the mechanisms underlying poor immune responses to the booster dose of the RTS,S malaria vaccine in African children. The key objectives are to: 1) identify specific antibody responses and functions that are suboptimal after the booster dose; 2)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,330 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research aimed at improving antibody-based vaccines and therapies against Plasmodium falciparum and Plasmodium vivax malaria. The funding will support the analysis of molecular properties associated with highly potent...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) will support research to define the immune response to Plasmodium vaccination and test an adjuvant to boost immunity against malaria. The $205,125 award to the Hennepin Healthcare Research Institute will utilize an improved small animal model to compare vaccine responses in specific pathogen-free (SPF) mice versus...
This Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to study molecular mechanisms of Plasmodium parasite invasion in Anopheles mosquito midguts to identify novel targets for transmission-blocking malaria vaccines. The key products and services to be delivered under this award include: Functional characterization of identified mosquito and parasite proteins that mediate...
This $244,440 federal Project Grant was awarded on January 14, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant was awarded to the Albert Einstein College of Medicine in Bronx, New York to conduct research on the role of cytolytic ZEB2+ memory CD4+ T cells in providing protection against the liver stage of malaria infection. The research seeks to gain insights into the cellular immune...
This $423,500 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Utah aims to investigate the role of invariant natural killer T (iNKT) cells in driving pathogenic CD8 T cell responses that contribute to cerebral malaria during Plasmodium infection. The central hypothesis is that iNKT cells, as innate-like T cells, act as an initial source of effector cytokines that shape the...